CZE < DEU < DNK

Facettes : Author.f AffPays.f

List of bibliographic references

Number of relevant bibliographic references: 26.
[0-20] [0 - 20][0 - 26][20-25][20-40]

Ident.	Authors (with country if any)	Title
000015 (2008)	Tim Bongartz [États-Unis] ; Josef S. Smolen [Autriche] ; Andre Beaulieu [Canada] ; Andrea Rubbert-Roth [Allemagne] ; Cesar Ramos-Remus [Mexique] ; Josef Rovensky [Slovaquie] ; Emma Alecock [Royaume-Uni] ; Thasia Woodworth [Royaume-Uni] ; Rieke Alten [Allemagne]	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Commentary
000023 (2008)	P. Emery [Royaume-Uni] ; E. Keystone [Canada] ; H. P. Tony [Allemagne] ; A. Cantagrel [France] ; R. Van Vollenhoven [Suède] ; A. Sanchez [Mexique] ; E. Alecock [Royaume-Uni] ; J. Lee [États-Unis] ; J. Kremer [États-Unis]	IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals : results from a 24-week multicentre randomised placebo-controlled trial
000059 (2009)	J. Braun [Allemagne] ; J. R. Kalden [Allemagne]	Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis
000063 (2010)	A. Gause [Allemagne] ; A. Rubbert-Roth [Allemagne] ; H. Michels [Allemagne] ; M. Gaubitz [Allemagne] ; W.-J. Mayet [Allemagne]	Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Einsatz von Tocilizumab bei der rheumatoiden Arthritis (Februar 2010)
000068 (2010)	J. Wollenhaupt [Allemagne] ; K. Krüger [Allemagne]	Nicht-TNF-Biologika in der Therapiestrategie bei rheumatoider Arthritis : Was kommt nach TNF-Blockern im klinischen Alltag ?
000069 (2010)	P. Roll [Allemagne] ; A. Rubbert-Roth [Allemagne] ; H.-P. Tony [Allemagne]	Tocilizumab: Was kommt nach TNF-Blockern im klinischen Alltag? : Was kommt nach TNF-Blockern im klinischen Alltag ?
000071 (2010)	Kay Stubenrauch [Allemagne] ; Uwe Wessels [Allemagne] ; Herbert Birnboeck [Suisse] ; Francisco Ramirez [Royaume-Uni] ; Angelika Jahreis ; Julia Schleypen [Allemagne]	Subset Analysis of Patients Experiencing Clinical Events of a Potentially Immunogenic Nature in the Pivotal Clinical Trials of Tocilizumab for Rheumatoid Arthritis: Evaluation of an Antidrug Antibody ELISA Using Clinical Adverse Event- Driven Immunogenicity Testing
000072 (2010)	G. Horneff [Allemagne]	Juvenile Arthritiden
000074 (2010)	Joerg C. Henes [Allemagne] ; Marius Horger [Allemagne] ; Ilhan Guenaydin [Allemagne] ; Lothar Kanz [Allemagne] ; Ina Koetter [Allemagne]	Mixed response to tocilizumab for ankylosing spondylitis
000104 (2011)	Gerd R. Burmester [Allemagne] ; E. Feist [Allemagne] ; H. Kellner [Allemagne] ; J. Braun [Allemagne] ; C. Iking-Konert [Allemagne] ; A. Rubbert-Roth [Allemagne]	Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase Illb real-life study (TAMARA)
000107 (2011)	K. Krüger [Allemagne]	Kombinationsbehandlung von Methotrexat mit DMARDs oder Biologika - Aktueller Stand : Aktueller Stand bei Methotrexat
000114 (2011)	Petra Roll [Allemagne] ; Khalid Muhammad [Allemagne] ; Mathias Schumann [Allemagne] ; Stefan Kleinert [Allemagne] ; Hermann Einsele [Allemagne] ; Thomas Dörner [Allemagne] ; Hans-Peter Tony [Allemagne]	In Vivo Effects of the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab on the B Cell Compartment
000119 (2011)	Khalid Muhammad [Allemagne] ; Petra Roll [Allemagne] ; Thomas Seibold [Allemagne] ; Stefan Kleinert [Allemagne] ; Hermann Einsele [Allemagne] ; Thomas Dörner [Allemagne] ; Hans-Peter Tony [Allemagne]	Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells
000130 (2011)	Christof Iking-Konert [Allemagne] ; Martin Aringer [Allemagne] ; Jurgen Wollenhaupt [Allemagne] ; Thomas Mosch [Allemagne] ; Stefan Tuerk [Allemagne] ; Eugen Feist [Allemagne] ; Gerd R. Burmester [Allemagne]	Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
000149 (2012)	Stefan Schanz [Allemagne] ; Marc Schmalzing [Allemagne] ; Emmanuella Guenova [Allemagne] ; Gisela Metzler [Allemagne] ; Anja Ulmer [Allemagne] ; Ina Kötter [Allemagne] ; Gerhard Fierlbeck [Allemagne]	Interstitial Granulomatous Dermatitis With Arthritis Responding to Tocilizumab
000162 (2012)	Veronika R. Lang [Allemagne] ; Matthias Englbrecht [Allemagne] ; Jürgen Rech [Allemagne] ; Hubert Nüsslein [Allemagne] ; Karin Manger [Allemagne] ; Florian Schuch [Allemagne] ; Hans-Peter Tony [Allemagne] ; Martin Fleck [Allemagne] ; Bernhard Manger [Allemagne] ; Georg Schett [Allemagne] ; Jochen Zwerina [Allemagne, Australie]	Risk of infections in rheumatoid arthritis patients treated with tocilizumab
000171 (2012)	Andrea Rubbert-Roth [Allemagne]	Assessing the safety of biologic agents in patients with rheumatoid arthritis
000172 (2012)	Karel Pavelka [République tchèque] ; Arthur F. Kavanaugh [États-Unis] ; Andrea Rubbert-Roth [Allemagne] ; Gianfranco Ferraccioli [Italie]	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
000177 (2012)	Charalampos Dragonas [Allemagne] ; Boris Ehrenstein [Allemagne] ; Martin Fleck [Allemagne]	Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection
000185 (2012)	Morten A. Karsdal [Danemark] ; Georg Schett [Allemagne] ; Paul Emery [Royaume-Uni] ; Olivier Harari [Royaume-Uni] ; Inger Byrjalsen [Danemark] ; Andy Kenwright [Royaume-Uni] ; Anne C. Bay-Jensen [Danemark] ; Adam Platt [Royaume-Uni]	IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522)
000186 (2012)	Vibeke Strand [États-Unis] ; Gerd R. Burmester [Allemagne] ; Sarika Ogale [États-Unis] ; Jenny Devenport [États-Unis] ; Ani John [États-Unis] ; Paul Emery [Royaume-Uni]	Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PascalFrancis/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/FA14s3.i -k "DEU" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/FA14s3.i  \
                -Sk "DEU" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    indexItem
   |index=    FA14s3.i
   |clé=    DEU
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021